The innate as well as adaptive immune response both has critical roles to fight against cancer. However, studies have shown that most effective tumor killing occurs when these work mutually.
“Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2028” Report Highlights:
- Commercialization Market Potential After Market Launch: > USD 4 Billion
- Insight on Key Drugs In Research & Development
- Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight
- Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies
- Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type
- Adopted Approaches for Gamma Delta T Cell Therapy
Download Report: https://www.kuickresearch.com/ccformF.php?t=1647514477
The innate as well as adaptive immune response both has critical roles to fight against cancer. However, studies have shown that most effective tumor killing occurs when these work mutually. The gamma delta T cells are unique subset of T cells which have properties of both responses. This combination of features conveys functional abilities that make them ideally suited for use in cell therapy against cancer. Since their characterization, researchers have indulged in research and development activities to utilize these cells as potential for development of novel cancer therapies. Currently, no such therapy utilizing gamma delta T cells has entered the market. However, more than 20 drugs are present in clinical pipeline which have shown promising results.
ADI-001 developed by Adicet Bio is one of the most promising candidates in development. ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a treatment for B-cell non-Hodgkin's lymphoma. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Recently, the company announced positive interim results from phase-I clinical trial. Apart from this, the company has also developed ADI-002, which is Glypican-3 (GPC3) targeted allogeneic, off-the-shelf gamma delta chimeric antigen receptor (CAR) T cell development candidate for solid tumors. Currently, ADI-002 is present in preclinical development and has demonstrated encouraging response.
US is currently dominating the global market which is mainly due to the large number of ongoing clinical trials, presence of key players in the region, and rising government initiatives. For instance in 2021, US FDA has granted orphan drug designations to two gamma delta T cell therapies including GDX012 and LAVA-051, which will expedite their development in the region. Apart from this, the orphan drug designation also provides several incentives to the company including patent exclusivity, research grants, tax credits, and assistance for clinical research. Apart from this, rising geriatric population and increasing awareness among the population will also boost the growth of market in the region.
In recent years, pharmaceutical companies have begun to embrace a more collaborative way of working to help overcome some of the challenges the industry is facing. In 2021, Takeda Pharmaceutical announced the exercise of its option to acquire GammaDelta Therapeutics. Through the acquisition, Takeda will obtain GammaDelta’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy platforms, which includes both blood-derived and tissue-derived platforms, in addition to early-stage cell therapy programs. Apart from this, Century Therapeutics and Bristol Myers Squibb announced a research collaboration and license agreement to develop and commercialize up to four induced pluripotent stem cell ("iPSC") derived, engineered natural killer cell ("iNK") and / or T cell ("iT") programs for hematologic malignancies and solid tumors. The first two programs include a program in acute myeloid leukemia and a program in multiple myeloma, which could incorporate either the iNK or a gamma delta iT platform.
As per our analysis, the global gamma delta T cell therapy market is expected to surpass US$ 5 Billion by 2028. This can be justified by the robust clinical pipeline of drugs including INB-200, LAVA-051, ADI-001, ACE1831, GDT-002, TCB002, LAVA-1207, and others. In addition to this, surge in incidences of cancer, growing awareness for cancer treatment, and high investment from government and other enterprises will also fuel the growth of market during the forecast period.
The global gamma delta T cell therapy report provide comprehensive insights into major drugs in clinical pipeline and key players operating in the market. This segment of the gamma delta T cell therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com